Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,776 questions · 7,311 findings · 959 reviews · Headline outcomes only

No studies found 1,498 · 20.5%GRADE not reported 303 · 4.1%Very low 1,839 · 25.2%Low 1,991 · 27.2%Moderate 1,277 · 17.5%High 403 · 5.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Anti‐TNF discontinuation vs anti‐TNF continuation

Proportion participants that switched to another biologic due to loss of response ‐ not measured · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐TNF discontinuation vs anti‐TNF continuation

Proportion of participants with minimal radiographic progression · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF discontinuation leads to higher proportion participants with minimal radiographic progression compared with anti‐TNF continuation (high certainty).

1 finding from 1 review

Anti‐TNF discontinuation vs anti‐TNF continuation

Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

It is very uncertain whether anti‐TNF discontinuation changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).

1 finding from 1 review

Anti‐TNF discontinuation vs anti‐TNF continuation

Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF discontinuation showed no clear difference in withdrawals due to adverse events compared with anti‐TNF continuation (moderate certainty).

1 finding from 1 review

Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation

Maintenance of clinical remission · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF disease activity–guided dose tapering showed no clear difference in proportion of participants with persistent remission compared with anti‐TNF continuation (high certainty).

1 finding from 1 review

Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation

Proportion of participants switched to another biologic due to loss of response · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF disease activity–guided dose tapering showed no clear difference in proportion of participants switched to another biologic due to loss… compared with anti‐TNF continuation (low certainty).

1 finding from 1 review

Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation

Proportion of participants with minimal radiographic progression · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF disease activity–guided dose tapering showed no clear difference in proportion of participants with minimal radiographic progression compared with anti‐TNF continuation (low certainty).

1 finding from 1 review

Anti‐TNF dose reduction vs anti‐TNF continuation

Maintenance of clinical remission · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF dose reduction showed no clear difference in proportion of participants with persistent remission compared with anti‐TNF continuation (low certainty).

1 finding from 1 review